ECCO-konferencen i København

| Henning Glerup | 11. Apr 2019 kl. 8:32 |

6.-9. marts blev der afholdt ECCO-kongres i Bella Centeret i København. Med 7960 registrerede deltagere var det den hidtil største kongres om inflammatoriske tarmsygdomme. ECCO er en europæisk faglig organisation med betydelig impact på fagområdet. Selve kongressen har ud over det lægefaglige program også selvstændige programmer for blandt andet IBD-interesserede sygeplejersker og diætister. Der er ...

In this MEDtalk professor Stefan Schreiber present a head-to-head study of the efficacy and safety of vedolizumab and adalimumab for treatment over 52 weeks in adults with moderately to severely active ulcerative colitis (UC). The first study to directly compare two biological agents in IBD. Click and hear the results. ...

This study addresses whether existing transcriptional profile scan improve and support the current definition of UC in remission apart from the today existing endoscopic, histological and laboratory scoring systems. In this MEDtalk Ruth Paulssen tells og presents that a gut–brain communication network is involved during remission beside the partial restoration of immunological functions and recovery ...

Previous reports have indicated that the treatment of patients with elderly-onset IBD, defined as patients diagnosed ≥60 years, differs from that of younger patients. This study aimed to assess the treatment of elderly-onset IBD during the first 3 years of follow-up, compared with IBD diagnosed in patients aged 15–39 and 40–59, in a European population-based ...

Is there a connection between biomarkers of collagen degradation and formation and disease activity in patients with Crohn’s disease, and can these biomarkers be used in monitoring and prediction of disease activity and in differentiation between patients with CD and healthy individuals? Click and hear Joachim Hoeg Mortensen give the ...

In this MEDtalk Brian Bressler present data from a multi-country, retrospective chart review study assessed the effectiveness and safety of vedolizumab compared with anti-tumour necrosis factors  agents in a real-world cohort of biologic-naïve Crohn’s disease patients. Click and hear the result. ...

Karoline Anisdahl, Oslo University Hospital,Norway, and her colleagues aimed to assess whether there was a change over time in the proportion of patients receiving biologics between 2011 and 2016 and if the preferred first-line biologic changed after the introduction of biosimilar infliximab. Click and hear the highlights from the ...

Decreased health-related quality of life was most prominently associated to bowel frequency during daytime, urgency of defaecation and blood in stool. Other symptoms such as bowel frequency during night-time and arthritis were associated for some health-related quality of life dimensions, and appear to vary between the sexes. Furthermore, female sex was an independent predictor of ...

In this Norwegian study Bjoern Moum and colleagues aimed to investigate the drug survival of biologics in a national cohort of patients with Crohn’s disease. Data were collected from the Norwegian Patient Registry (NPR) and the Norwegian Prescription Database. In total, 2444 CD patients were included in the study. After 3 years, the survival rate ...

The prognosis of paediatric onset IBD remains uncertain. In this studi Tine Jess and colleague examined the overall and site-specific cancer risk among paediatric onset IBD patients when compared with non-IBD individuals from the general population. The risk was highest for liver, upper gastrointestinal, small bowel and colorectal cancer and was not influenced by medical ...

#Seneste udgivelse

Lungemedicin

Nr. 7 • juni 2019
13. årgang
  • KOL
  • Pneumoni
  • Iltbehandling
#

Almen praksis

Bo Gerdes

Bo Gerdes
praktiserende læge

Dorte Halkjær

Dorte Halkjær
praktiserende læge

Jens Georg Hansen

Jens Georg Hansen
overlæge, dr.med., speciallæge i almen medicin

  Tina Enevoldsen

Tina Enevoldsen
praktiserende læge